Literature DB >> 23392722

Minimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocol.

Xin Chen1, Shi-Ling Chen2, Yu-Xia He1, De-Sheng Ye1.   

Abstract

This paper was aimed to study the minimum dose of human chorionic gonadotropin (hCG) to effectively trigger maturation of oocytes and prevent ovarian hyperstimulation syndrome (OHSS) in a series of hyper-responders treated with a long gonadotropin releasing hormone agonist (GnRHa) protocol. Six women at high risk of developing severe OHSS in a long GnRHa protocol were enrolled into this study. Serum hormone levels on the day of and after hCG administration, antral follicle count, oocyte retrieval number and quality were determined. In total, 6 women aged between 29 and 36 years and at risk of developing severe OHSS, received 2000 U hCG. Five of them were treated with coasting for 1 day and the rest one for 4 days. The mean number of oocytes collected was 19 (range 14-27) and the fertilization rate per collected oocyte was 72.81%. Of the 6 women in the study, only one cancelled embryos transfer and all embryos were frozen, and then she delivered two health boys on term in the subsequent frozen-thawed embryo transfer (FET) cycle. Pregnancies and births were achieved in 3 patients out of 5 in vitro fertilization-embryo transfer (IVF-ET) cycles. No woman developed moderate or severe OHSS. Triggering with 2000 U hCG is feasible to prevent OHSS in unpredicted hyper-responders undergoing IVF in a long GnRHa protocol.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392722     DOI: 10.1007/s11596-013-1085-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  13 in total

Review 1.  Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing?

Authors:  Juan A García-Velasco; Verónica Isaza; Guillermo Quea; Antonio Pellicer
Journal:  Fertil Steril       Date:  2006-03       Impact factor: 7.329

2.  Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome.

Authors:  Dietmar Spitzer; Johannes Wogatzky; Maximilian Murtinger; Mathias H Zech; Robert Haidbauer; Nicolas H Zech
Journal:  Fertil Steril       Date:  2011-03-15       Impact factor: 7.329

3.  Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention.

Authors:  R G Forman; R Frydman; D Egan; C Ross; D H Barlow
Journal:  Fertil Steril       Date:  1990-03       Impact factor: 7.329

4.  The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles.

Authors:  Ulun Ulug; Mustafa Bahceci; Halit F Erden; Eliezer Shalev; Izhar Ben-Shlomo
Journal:  Hum Reprod       Date:  2002-02       Impact factor: 6.918

5.  The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program.

Authors:  H I Abdalla; M Ah-Moye; P Brinsden; D L Howe; F Okonofua; I Craft
Journal:  Fertil Steril       Date:  1987-12       Impact factor: 7.329

Review 6.  Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome.

Authors:  Mohamed Afm Youssef; Hesham G Al-Inany; Johannes Lh Evers; Mohamed Aboulghar
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

7.  Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles.

Authors:  Geeta Nargund; Lee Hutchison; Rex Scaramuzzi; Stuart Campbell
Journal:  Reprod Biomed Online       Date:  2007-06       Impact factor: 3.828

8.  Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.

Authors:  David W Schmidt; Donald B Maier; John C Nulsen; Claudio A Benadiva
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

9.  Does coasting, a procedure to avoid ovarian hyperstimulation syndrome, affect assisted reproduction cycle outcome?

Authors:  Nafiye Yilmaz; Dilek Uygur; Emre Ozgu; Sertac Batioglu
Journal:  Fertil Steril       Date:  2009-04-18       Impact factor: 7.329

10.  Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.

Authors:  Hwa Sook Moon; Bo Sun Joo; Sung Eun Moon; Su Kyung Lee; Kyung Seo Kim; Ja Seong Koo
Journal:  Fertil Steril       Date:  2008-04-25       Impact factor: 7.329

View more
  4 in total

1.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

2.  An update on the prevention of ovarian hyperstimulation syndrome.

Authors:  Omar El Tokhy; Julia Kopeika; Tarek El-Toukhy
Journal:  Womens Health (Lond)       Date:  2016-08-19

3.  Reducing the trigger dose of recombinant hCG in high-responder patients attending an assisted reproductive technology program: an observational study.

Authors:  Gian Mario Tiboni; Enrica Concetta Colangelo; Adalisa Ponzano
Journal:  Drug Des Devel Ther       Date:  2016-05-18       Impact factor: 4.162

Review 4.  Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management.

Authors:  Bahia Namavar Jahromi; Mohammad Ebrahim Parsanezhad; Zahra Shomali; Pardis Bakhshai; Mahshid Alborzi; Najmeh Moin Vaziri; Zahra Anvar
Journal:  Iran J Med Sci       Date:  2018-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.